A JAK inhibitor for CRS and ICANS prevention; ChAdOx1-platelet interactions and post-vaccination arterial thrombosis; lineage switch, an emerging mechanism of leukemia relapse
This episode discusses a JAK inhibitor, itacitinib, for preventing CRS and neurotoxicity in CAR T-cell therapy. It also covers the interaction between ChAdOx1 and platelets, potentially causing thrombosis, and explores lineage switch as a mechanism for leukemia relapse…